Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.63) by 7.98 percent. This is a 33.93 percent decrease over losses of $(1.12) per share from the
Cytokinetics lost less money per share than people expected, and made way more sales than predicted. When a company beats on both counts, it shows their business plan is working better than experts thought.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.